Skip to main content
Clinical Trials/NCT00959374
NCT00959374
Completed
Not Applicable

A Prospective, Randomized Study to Evaluate Dermal Closure With an Absorbable Barbed Suture (V-Loc 180 Absorbable Wound Closure Device or V-Loc 90 Absorbable Wound Closure Device) as Compared to a Conventional Absorbable Suture

Medtronic - MITG8 sites in 2 countries229 target enrollmentAugust 2009

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Breast Ptosis
Sponsor
Medtronic - MITG
Enrollment
229
Locations
8
Primary Endpoint
Total Dermal Closure Time
Status
Completed
Last Updated
13 years ago

Overview

Brief Summary

The objective of this study is to evaluate the use of an absorbable barbed suture as compared to a conventional absorbable suture when used for dermal closure during certain body contouring procedures.

Detailed Description

One of the greater common challenges of a surgical procedure is to effectively and efficiently close wounds across various levels of muscle, fat, fascia and/or skin. Surgical sutures continue to be the material of choice for wound closure. However, complications of sutures are those associated with tying knots to secure the suture. Examples of associated suture complications, although not comprehensive, include knot breakage and slippage, suture extrusion or spitting, infection, ischemia and scarring, reduced wound strength and inflammation and dehiscence. Both interrupted and continuous suture patterns require knots for suture line security when conventional suture constructs are used. Barbed sutures are designed to eliminate the need for tying knots during closure, thus ameliorating the detrimental aspects of knots.

Registry
clinicaltrials.gov
Start Date
August 2009
End Date
February 2012
Last Updated
13 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Subject must be 18 years of age or older.
  • Subject must be in good overall health.
  • Subject must be scheduled for individual or combined abdominoplasty, reduction mammaplasty, or mastopexy, other than concentric mastopexy, crescent mastopexy, or mastopexy with implants.
  • Subject must be willing to participate in the study, comply with study requirements, follow-up schedule, and give written informed consent.

Exclusion Criteria

  • Subject is pregnant or breast-feeding.
  • Subject has active infectious collagen diseases (i.e. scleroderma) or any other condition that would interfere with wound healing.
  • Subject has significant anatomic asymmetry that creates markedly different wound tension and/or geometry between the right and left side.
  • Subject is allergic to the test suture made of glycolide and trimethylene carbonate or the control suture made of glycolide and epsilon-caprolactone.
  • Subject has a BMI ≥
  • Subject has diabetes requiring medication for glycemic control.
  • Subject has a fever (temperature \> 38ºC), active skin infection or systemic infection at the time of surgery.
  • Subject underwent chemotherapy or radiation within the last 6 months.
  • Subject has a history of keloid or hypertrophic scar formation or other dermatologic conditions known to impair wound healing.
  • Subject has a history of alcohol or drug abuse within 6 months prior to screening.

Outcomes

Primary Outcomes

Total Dermal Closure Time

Time Frame: At time of surgery

In calculating the total dermal closure time, only the intradermal closure time is used for those subjects that did not have the deep dermal layer closed.

Secondary Outcomes

  • Cosmesis(12 weeks)

Study Sites (8)

Loading locations...

Similar Trials